- $37.09m
- $17.20m
- $12.29m
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Elutia Secures $15 Million Loan Financing From Avenue Capital Group
Elutia's Q2 revenue falls on SimpliDerm production disruption
Elutia Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Elutia Signs Definitive Agreement To Sell Simpliderm® In Transaction Valued At Up To $11 Million, Strengthening Balance Sheet Ahead Of NXT-41X Launch
Elutia Q1 net loss widens on non-cash warrant revaluation loss
Elutia Q4 revenue rises on higher cardiovascular product sales
Brief: Elutia Regains Compliance With Nasdaq Listing Requirements
Brief: Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, And Upcoming Nxt-41X Milestones
Elutia Q3 revenue falls short of estimates, gross margin improves
Brief: Elutia Q3 Revenue USD 3.323 Million
Brief: Elutia Appoints Accomplished MedTech Veteran Guido J. Neels To Board Of Directors
Brief: Elutia Announces Closing Of Bioenvelope Business Sale To Boston Scientific Corporation
Brief: Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
Brief: Elutia Enters Fifth Amendment To Credit Agreement
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Elutia Inc expected to post a loss of 17 cents a share - Earnings Preview
Elutia Inc expected to post a loss of 17 cents a share - Earnings Preview
Elutia Inc expected to post a loss of 17 cents a share - Earnings Preview